January 10, 2017: In a JPM slide presentation, Horizon Pharma says it’s on track to deliver $2 billion in total net sales by 2020.
December 22, 2016: Horizon Pharma announces that it has received a Notice of Allowance from the United States Patent and Trademark Office for U.S. patent application number 13/610,580, entitled “Methods of Therapeutic Monitoring of Phenylacetic Acid Prodrugs” that covers Horizon’s U.S. approved medicine RAVICTI (glycerol phenylbutyrate) Oral Liquid.
This Notice of Allowance concludes the substantive examination of the patent application and will result in the issuance of a U.S. patent after administrative processes are completed. The U.S. patent scheduled to issue from this application will expire on September 22, 2030. After issuance, Horizon plans to list the U.S. patent in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, or Orange Book.
December 22, 2016: Horizon Pharma announces that QUINSAIR (levofloxacin inhalation solution) is now available in Canada for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis. QUINSAIR is the first inhaled fluoroquinolone antibiotic to receive marketing authorization from Health Canada.
December 16, 2016: Jefferies making positive comments about Horizon Pharma; Reiterates Buy rating and sets price target of $26. Express Scripts updated its 2017 Preferred Drug List exclusions and Horizon garnered coverage for its primary care and rheumatology products.
Horizon Pharma Stock Chart
The Finviz screener settings used to find Horizon Pharma are: Sector Healthcare, Foward P/E Under 10, EPS growth this year 100% – 110%, Sales growth past 5 years 210% – 220%
Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets 11 medicines through its orphan, rheumatology and primary care business units.